

Personalized solutions for hematologic malignancies

A blue molecular structure graphic consisting of interconnected circles and lines, resembling a network or a chemical structure, located in the bottom left corner.

Trust the experts, with over 20 years of expertise.

Every patient is unique – your testing should be too

The Compass suite of services is focused on your patient's individual characteristics and is guided by board-certified hematopathologists with expertise in diagnosing hematologic malignancies and supporting clinical decision-making. This consultative service will result in a final report and definitive diagnosis for your patient.



Due to the significant overlap in disease presentation, hematological disorders and malignancies can be initially misdiagnosed. With over 100 different subtypes of leukemias, lymphomas, and myelomas, reaching a definitive diagnosis requires expertise to manage ever-evolving clinical guidelines and testing criteria.

Compass

- A sample-to-diagnosis service guided by board-certified hematopathologists to arrive at a definitive and actionable diagnosis for over 100 different types of hematologic malignancies.
- Only medically necessary tests are performed based on clinical history, laboratory information, and recommended guidelines.
- Available for bone marrow and peripheral blood specimens.

Compass Select

- A diagnostic solution designed to support pathologists. With Compass Select, hematopathologists at NeoGenomics will integrate existing morphologic testing completed locally with our comprehensive testing menu to arrive at a definitive diagnosis.
- A single report will include a final and definitive diagnosis and comprehensive assessment with actionable diagnostic and prognostic information without unnecessary testing.

Chart®


- Monitor your patient's progression through a specialized report comparing multiple evaluations with insights from first diagnosis to current state. Chart is a specialized report uniquely for Compass patients.
- A premier service for monitoring response to therapy, assessing residual disease, and determining disease progression. This is a solution for any patient with a hematologic malignancy requiring long-term disease assessment and evaluation of treatment efficacy.
- Automatically performed on samples when there is a prior Compass report for the patient.

Client notification of acute cases occurs within 24 hours of sample receipt.



Guided by board-certified hematopathologists, the Compass report will include a final and definitive diagnosis and comprehensive assessment with actionable diagnostic and prognostic information, allowing peace of mind for you and your patient.

- 1 Final diagnosis
- 2 Comprehensive assessment
- 3 Testing results from modalities utilized



Chart, a specialized report designed specifically for **Compass** patients to monitor progression, comparing multiple evaluations with insights from first diagnosis to current state.

Final Diagnosis: Leukopenia and anemia, history of CML			
Comprehensive Assessment			
CBC shows leukopenia and anemia, history of CML. The concurrent flow cytometry (8888888 / XXX88-888888) shows no diagnostic immunophenotypic abnormalities detected. Morphological findings are consistent with CML after treatment. Molecular study for BCR/Abi history is positive, which indicates residual disease.			
	6666666 02/04/2021	7777777 02/18/2021	8888888 04/08/2021
Diagnosis	- Chronic myeloid leukemia (CML)	Chronic myeloid leukemia, BCR-ABL1+, chronic phase.	Leukopenia and anemia, history of CML
Morphology	PERIPHERAL BLOOD SMEAR REVIEW: - Basophilia, 12% - Leukocytosis and left-shifted myeloid maturation - Thrombocytosis, moderate - Normocytic anemia, moderate with anisopoikilocytosis	BONE MARROW, LEFT ILIAC CREST, CORE BIOPSY AND ASPIRATE SMEARS: -Hypercellular bone marrow for age (~95%) with myeloid hyperplasia and atypical megakaryocytic hyperplasia, consistent with chronic myeloid leukemia.	PERIPHERAL BLOOD SMEAR REVIEW: Leukopenia and anemia, history of CML: - Mild leukopenia with maturation. - Normal platelets and normal lymphocytes. - Anisocytosis of RBCs. - No circulating blasts.
Flow Cytometry	Left-shifted myeloid maturation pattern with 10.9% basophils	1. NO DIAGNOSTIC IMMUNOPHENOTYPIC ABNORMALITIES DETECTED 2. NO INCREASED BLASTS DETECTED	No diagnostic immunophenotypic abnormalities detected.

We pride ourselves on our unparalleled client services team. If you have questions regarding test information, specimen requirements, turnaround times, test add-ons, and patient results, please contact us:

Client.Services@NeoGenomics.com or call 866.776.5907, option 3.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and oncology data solutions. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service, sample-processing laboratory in Cambridge, England, United Kingdom.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phn: 866.776.5907
Fax: 239.690.4237

NeoGenomics.com

©2026 NeoGenomics Laboratories, Inc. All rights reserved.
All trademarks are the property of their respective owners.
CORP-MRKT-0067 05.26